Stocktoria
IRIDEX CORP IRIX
IRIDEX CORP (IRIX) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2026 revenue was $52.7M at a -8.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.65 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.413 |
| Retained earnings / assets | -3.171 |
| EBIT / assets | -0.088 |
| Equity / liabilities | 0.203 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| IRIX | IRIDEX CORP | 4/9 | -8.01 | — | +8.2% |
| ELMD | Electromed, Inc. | 6/9 | 10.99 | 46.4 | +17% |
| FOCL | EDAP TMS SA | 3/9 | -5.4 | — | +1.6% |
| STXS | Stereotaxis, Inc. | 4/9 | — | — | +20.3% |
| ECOR | electroCore, Inc. | 4/9 | — | — | +27.2% |
| POCI | PRECISION OPTICS CORPORATION, INC. | 3/9 | -8.27 | — | -0.1% |
| QTI | QT IMAGING HOLDINGS, INC. | 5/9 | -4.34 | — | — |
About IRIDEX CORP
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. In addition, it offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform transscleral laser therapy; G-Probe and G-Probe Illuminate, which are used in procedures to treat uncontrolled and refractory glaucoma; and EndoProbe family of products that are used for endophotocoagulation. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics through direct and independent sales force in the United States, as well as through independent distributors internationally. It operates in the United States, Europe, the Middle East, Africa, the Asia/Pacific region, and the Americas. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
FAQ
Is IRIX financially healthy?
IRIDEX CORP's Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does IRIX pay a dividend?
No, IRIDEX CORP does not currently pay a dividend.
How profitable is IRIX?
In FY2026, IRIDEX CORP had a net margin of -8.4% and a return on equity of -90.1%.
Is IRIX overvalued or undervalued?
IRIDEX CORP trades at about 17.4× trailing earnings — below its 10-year norm (10-year range 9.3×–192.6×, median 26.2×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for IRIX?
The average Wall-Street price target for IRIDEX CORP is $2.75, about 217.0% above the recent price, from 1 analysts.
Is IRIX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on IRIDEX CORP: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2026-01-03. Facts plus Stocktoria's own computed scores — not investment advice.